STATEMENT OF NEED
Of the estimated 228,150 patients diagnosed with lung cancer in the United States each year, 84% have non-small cell lung cancer (NSCLC). Most patients with NSCLC present with advanced disease, which is highly resistant to chemotherapy. The 5-year survival rates remain dismal (18%). Recently, the use of tumor histology in determining optimal treatment strategies and relevant molecular biomarkers to further refine selection of novel therapies has improved outcomes for some patients. However, a number of targeted treatments are not applicable to patients without driver mutations. For such patients, treatment after first-line platinum-based chemotherapy involves immunotherapies targeting the PD-1/PD-L1 pathways; antiangiogenic agents have also shown promise. The use of immunotherapies (eg, checkpoint inhibitors) makes molecular testing essential to guiding clinical management. Whereas several studies have demonstrated that tumor mutation burden has been associated with checkpoint inhibitor efficacy, uptake in testing for this biomarker is limited. The bleak survival rates for NSCLC also indicate a need for continued development of more effective approaches to tumor control.
Oncology physicians, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).
Upon completion of this activity, participants should be able to:
Jamie E. Chaft, MD (Chairperson)
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
Jyoti D. Patel, MD
Professor of Medicine
Taofeek K. Owonikoko, MD, PhD, MSCR
Professor, Hematology & Medical Oncology
Emory University School of Medicine
Kathryn C. Arbour, MD
Memorial Sloan Kettering Cancer Center
There is no fee to participate in or claim CME credit for this activity.
Please note that the i3 Health does not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1.5 ILNA points toward:
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with commercial interests that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Jamie E. Chaft, MD, discloses that she has received research support from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck.
Jyoti D. Patel, MD, discloses that she has served on the advisory board for AstraZeneca.
Taofeek Owonikoko, MD, PhD, MSCR, discloses that he has served on the advisory board for Abbvie, Amgen, ARMO BioSciences, AstraZeneca, Bayer, BerGenBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, EMD Serono, G1 Therapeutics, Heron Pharmaceutical, Lilly, MedImmune, Novartis, PharmaMar, Sandoz, Seattle Genetics, Takeda, and Xcovery. He has also served on the data and safety monitoring board for EMD Serono and Roche/Genetech. Dr. Owonikoko has received research support from Abbvie, Aeglea Biotherapeutics, Amgen, Astellas Pharma, AstraZeneca/MedImmune, Bayer, Bristol-Myers Squibb, Celgene, Corvus Pharmaceuticals, Fujifilm, G1 Therapeutics, Incyte, Loxo/Lilly, Merck, Novartis, Pfizer, Regeneron, Stem CentRx, and United Therapeutics. He also has ownership interest in Cambium Medical Technologies.
Kathryn C. Arbour, MD, discloses that she has served on the advisory board for AstraZeneca. She has received research support from NKTR, Takeda, and Novartis (to institution).
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
UNAPPROVED USE DISCLOSURE
i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an independent educational grant from Lilly.
Aggregate participant data will be shared with commercial supporters of this activity.
AMERICANS WITH DISABILITIES ACT